• BrainStorm Cell Therapeutics posted a Q2 net loss of USD 3.9 million, widening from USD 2.9 million a year earlier.
• General and administrative costs climbed to USD 2.7 million from USD 1.5 million; R&D spend edged down to USD 1 million from USD 1.1 million.
• Net loss per share was USD (0.35), versus USD (0.34) in the prior-year quarter.
• Cash, cash equivalents and restricted cash fell to about USD 200,000 at June 30, from about USD 1.03 million a year earlier.
• BrainStorm is preparing to open enrollment for the Phase 3b ENDURANCE trial of NurOwn in ALS under an FDA Special Protocol Assessment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608141600PR_NEWS_USPR_____LN26654) on August 14, 2026, and is solely responsible for the information contained therein.